Comparing two treatments for young children with medulloblastoma
Part of Cancer clinical trials.
This trial compares two standard treatment plans for young children with a specific type of medulloblastoma (a brain tumor). It looks at how each treatment affects thinking and learning over time, to see which one helps children do better in the long run.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 5 years old when diagnosed with medulloblastoma (a type of brain tumor).
- The tumor must be a specific subtype called "SHH-activated" (this is a lab test result).
- Your child must not have been treated for any other brain tumor or cancer before.
- The cancer must not have spread outside the brain (no metastasis).
- Your family must be able to attend regular follow-up visits for thinking and learning tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This study looks at how young people with certain brain tumors respond to treatment. It aims to understand why some tumors resist therapy, which may help improve future treatments.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.